热门资讯> 正文
安捷伦获得FDA批准Tecelra配套诊断产品
2024-08-03 00:46
- Agilent (NYSE:A) has received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx as a diagnostic tool to help identify patients who may be eligible for treatment with Adaptimmune Therapeutics’ (NASDAQ:ADAP) newly approved gene therapy Tecelra.
- Adaptimmune (ADAP) announced late Thursday that it had received FDA accelerated approval for Tecelra. The product is approved for the treatment of advanced MAGE-A4 positive synovial sarcoma in adults with certain HLA types who have received prior chemotherapy.
More on Agilent Technologies
- Agilent: Making A Move To Ignite Some Growth
- Agilent Hit By Cyclical Headwinds, But The Growth Story Remains Intact Long Term
- Agilent Technologies, Inc. (A) Jefferies 2024 Global Healthcare Conference (Transcript)
- Agilent acquires Sigsense to boost AI capabilities for lab operations
- Agilent to acquire North American CDMO BIOVECTRA for $925 million
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。